Serenex has named Elizabeth Wyatt, a former executive with Merck & Co., to the company’s board of directors.

At Merck, Wyatt was increasingly responsible for business development and licensing activities and was most recently vice president of corporate licensing.

Wyatt also serves on the boards of directors of Ariad Pharmaceuticals, Neose Technologies, and Medimmune, and on the board of trustees of Randolph-Macon College.

“I am very pleased that Elizabeth is joining the Serenex board of directors,” said Richard Kent, president and CEO of Serenex. “The wealth of pharmaceutical and business experience she brings is especially appropriate at this juncture in the company’s development, particularly as out drug discovery programs gain momentum. I am thrilled that she will now be part of out strategic decision making.”

Based in Durham, Serenex is a drug discovery company employing proprietary and novel chemoproteomics technology in such areas as oncology and anti-inflammation.